1887

Abstract

Biofilms are sessile communities of microorganisms embedded within a self-generated extracellular polymeric matrix. Such biofilms are found for instance in adults with cystic fibrosis, with pulmonary infections with the Gram-negative bacterium Pseudomonas aeruginosa being particularly common. This infection in CF patients is commonly managed with antibiotic dry powder inhalers, one of which is the aminoglycoside tobramycin. The activity of tobramycin has been well characterized in vitro, but current models that have been used are not very representative for lung infections, and better models would provide a significant advantage as these could be used, for instance, to improve the formulation of dry powder inhalers. For instance, one question that has not been addressed with current models is whether the size of drug particles emitted from a dry powder inhaler influences the efficacy of the anti-biofilm activity of the antibiotic. In this project, we utilized the Next Generation Impactor (NGI), which is a pharmaceutical instrument used to separate particles into size fractions. We used the NGI to separate tobramycin particles into different sizes and tested the influence of these particles on eradication of P. aeruginosa biofilms, which were grown using as colony biofilms that closely mimics conditions in the lung where biofilms are grown on a substrate-air interface. Preliminary evidence indicated smaller tobramycin particles are better in eradication of P. aeruginosa biofilms as compared to larger particles. Our results may represent a step towards improving the formulation of tobramycin dry powder inhalers to be effective in eradicating P. aeruginosa biofilms.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.ac2019.po0039
2019-04-08
2024-03-29
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.ac2019.po0039
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error